Modified FOLFOX6 with or Without Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Multicenter Randomized Trial.

Yanhong Deng,Pan Chi,Ping Lan,Lei Wang,Weiqing Chen,Long Cui,Daoda Chen,Jie Cao,Hongbo Wei,Xiang Peng,Zonghai Huang,Guanfu Cai,Ren Zhao,Zhongcheng Huang,Yiding Luo,Hongfeng Zhou,Yisheng Wei,Hao Zhang,Jian Zheng,Jianping Wang

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.3502

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:3502 Background: The FOWARC trial compared FOLFOX6 with or without Radiation in neoadjuvant treatment of locally advanced rectal cancer to 5-FU chemoradiotherapy. First results of early secondary endpoints have been published (Deng et al., JCO 2016). Here we present the primary endpoint, disease-free survival (DFS) at 3 years. Methods: Between 01/2011-02/2015, patients with rectal cancer within 12 cm from the anal verge, clinical stage II-III were randomly assigned to received 5-FU with radiation(RT) (FU-RT arm), or receive mFOLFOX6 with RT (FOLFOX-RT arm), or receive 4-6 cycles of mFOLFOX6 alone (FOLFOX arm), peri-operative RT was allowed if needed. The primary endpoint was DFS at 3 years defined as the interval from randomization to incomplete surgical resection, locaregional or metastatic recurrence or death, whichever occurred first. Results: A total of 495 patients were randomly assigned to three arms at 1:1:1 ration. 418 patients who had available follow up and obeyed the treatment protocol, 130 in FU-RT arm, 142 in FOLFOX-RT arm and 146 in FOLFOX arm. The local recurrence rate was 10.0%, 8.5% and 8.9% respectively. After a median follow-up time of 45.2 months, 35 patients in FU-RT arm had a DFS-related event, as compared with 37 patients in FOLFOX-RT arm(HR 1.031, 95% confidence interval 0.657 to 1.620), and 41 in FOLFOX arm (HR 0.960, 95% confidence interval 0.615 to 1.497). The rate of DFS at three years was 76.4±3.8% in FU-RT arm, 77.8±3.5% in FOLFOX-RT arm and 75.7±3.6% in FOLFOX arm (P = 0.961 by the exact stratified log-rank test). The rate of OS at three years was 93.7±2.2% in FU-RT arm, 92.0±2.3% in FOLFOX-RT arm and 92.2±2.3% in FOLFOX arm (P = 0.961 by the exact stratified log-rank test). Conclusions: FOLFOX with or without radiation did not improve significantly improved DFS in patients with advanced rectal cancer. However, FOLFOX alone seems to have identical local recurrence rate and 3-DFS and 3-OS compared to standard FU-RT. Clinical trial information: NCT01211210.